The company’s managing director, Dr. Sharvil Patel, announced that Zydus plans to launch market-specific dosage variants of the Semaglutide rather than a uniform product. This approach, he explained, is part of a broader strategy to offer differentiated formulations that provide significant benefits over existing products. In a key innovation, Zydus has also developed a novel, all-in-one pen device that can deliver multiple dose strengths, eliminating the need for patients to use separate pens. This is expected to enhance convenience and affordability, particularly for the Indian market, which Dr. Patel anticipates will be the company’s primary revenue driver. Regulatory filings are set to begin by the end of the year.
Biotech Express
ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.